Thomas D. Ingolia
Keine laufenden Positionen mehr
Profil
Thomas D.
Ingolia served as Chief Executive Officer at Medisyn Technologies, Inc. and Sphinx Pharmaceuticals Corp.
He was also President & Chief Executive Officer at Prolexys Pharmaceuticals, Inc. In 2006-2007, he served as Chairman at Zivo Bioscience, Inc. Ingolia holds an MBA from Indiana University, a doctorate from the University of California, Berkeley, and an undergraduate degree from the University of Illinois.
Ehemalige bekannte Positionen von Thomas D. Ingolia
Unternehmen | Position | Ende |
---|---|---|
ZIVO BIOSCIENCE, INC. | Vorsitzender | 01.09.2007 |
Sphinx Pharmaceuticals Corp | Präsident | - |
Medisyn Technologies, Inc.
Medisyn Technologies, Inc. Pharmaceuticals: MajorHealth Technology Medisyn Technologies, Inc. develops novel pharmaceuticals, nutraceuticals, and animal health products. The firm engages in the development of pre-qualified proprietary drug compounds. Its Forward Engineering platform is focused on predicting the behavior of molecules from topology. The company was founded in 1999 and is headquartered in Minnetonka, MN. | Vorsitzender | 13.08.2010 |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Präsident | - |
Ausbildung von Thomas D. Ingolia
University of California, Berkeley | Doctorate Degree |
Indiana University | Masters Business Admin |
University of Illinois | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ZIVO BIOSCIENCE, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Health Technology |
Medisyn Technologies, Inc.
Medisyn Technologies, Inc. Pharmaceuticals: MajorHealth Technology Medisyn Technologies, Inc. develops novel pharmaceuticals, nutraceuticals, and animal health products. The firm engages in the development of pre-qualified proprietary drug compounds. Its Forward Engineering platform is focused on predicting the behavior of molecules from topology. The company was founded in 1999 and is headquartered in Minnetonka, MN. | Health Technology |
Sphinx Pharmaceuticals Corp | Health Technology |